An observational study in Heart Failure and Aortic Stenosis, sponsored by IRCCS Policlinico S. Donato. Recruiting at 2 sites in Italy. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-30.
Sponsored by IRCCS Policlinico S. Donato · Observational
This study is aimed to investigate the global transcriptome in order to determine the expression profile of messenger RNAs (mRNAs), as well as long noncoding- (lncRNAs) and micro noncoding-RNAs (miRNAs) in heart failure (HF) and in aortic stenosis (AS). The aim is to clarify their role in cardiac disease pathogenesis, as well as their potential as biomarkers. To this purpose, both tissue and blood specimens will be collected and patients will be compared to individuals not affected by cardiovascular diseases.
The investigators will collect plasma and cardiac tissue specimens from consenting subjects. The investigators will evaluate the expression of mRNAs, miRNAs and lncRNAs in patients affected by both end-stage and not end-stage HF as well as in patients affected by aortic stenosis and undergoing valve replacement and requiring cardiac myectomy. The tissue dysregulated RNAs will be next measured in plasma samples in order to clarify their potential as biomarkers.
Cardiac surgery patients
Non end-stage heart failure
End-stage heart failure
Aortic Stenosis
Exclusion Criteria:
Non end-stage heart failure
End-stage heart failure
Aortic Stenosis
Measurement of RNAs in non end-stage heart failure patients undergoing to left ventricle reconstruction
Diagnostic Test: measurement of RNAs
Measurement of RNAs in end-stage heart failure patients undergoing to left ventricular assisted device (LVAD)
Diagnostic Test: measurement of RNAs
Measurement of RNAs in patients affected by cardiac hypertrophy leading to aortic stenosis and requiring cardiac myectomy
Diagnostic Test: measurement of RNAs
Measurement of RNAs in individuals not affected by cardiovascular diseases
Diagnostic Test: measurement of RNAs
Cardiac tissutal mRNAs signatures
The mRNAs cardiac tissutal signatures of non- and end-stage heart failure patients and of aortic stenosis patients compared to controls
Time frame: from Year 1 to Year 3
Cardiac tissutal miRNAs signatures
The miRNAs cardiac tissutal signatures of non- and end-stage heart failure patients and of aortic stenosis patients compared to controls
Time frame: from Year 1 to Year 3
Cardiac tissutal lncRNAs signatures
The lncRNAs cardiac tissutal signatures of non- and end-stage heart failure patients and of aortic stenosis patients compared to controls
Time frame: from Year 1 to Year 3
Non end-stage, end-stage heart failure, aortic stenosis mRNAs signatures in plasmas
The mRNAs dysregulated in cardiac tissues will be measured in blood plasma samples of non- and end-stage heart failure patients and of aortic stenosis patients compared to controls
Time frame: from Year 3 to Year 5
Non end-stage, end-stage heart failure, aortic stenosis miRNAs signatures in plasmas
The miRNAs dysregulated in cardiac tissues will be measured in blood plasma samples of non- and end-stage heart failure patients and of aortic stenosis patients compared to controls
Time frame: from Year 3 to Year 5
Non end-stage, end-stage heart failure, aortic stenosis lncRNAs signatures in plasmas
The lncRNAs dysregulated in cardiac tissues will be measured in blood plasma samples of non- and end-stage heart failure patients and of aortic stenosis patients compared to controls
Time frame: from Year 3 to Year 5
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Policlinico S. Donato